Optimization of a refolding step for a therapeutic fusion protein in the quality by design (QbD) paradigm.

Production of biotech therapeutics in Escherichia coli involves protein expression as insoluble inclusion bodies that need to be denatured and the resulting protein refolded into the native structure. In this paper, we apply a Quality by Design approach using Design of Experiments for optimization of the refolding process for a recombinant biotech therapeutic, granulocyte colony stimulating factor. First, risk analysis was performed to identify process parameters that require experimental examination. Next, the chosen parameters were examined using a fractional factorial screening design. Based on the results of this study, parameters that have significant effect on refold yield and product quality were identified and examined using a full factorial Design of Experiments for their interactions. The final model was statistically significant and delivered a refolding yield of 77%. Further, kinetics of refolding was evaluated under optimal conditions and was found to be of first order with a rate constant of 0.132/min. Design space was established for the three parameters for a given permissible range of yield, protein concentration, and purity. The primary objective of this paper is to provide a roadmap for implementing Quality by Design for development of a protein refolding step.

[1]  Chaozhan Wang,et al.  High Recovery Refolding of rhG‐CSF from Escherichia coli, Using Urea Gradient Size Exclusion Chromatography , 2008, Biotechnology progress.

[2]  A. Panda,et al.  Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli. , 2003, Advances in biochemical engineering/biotechnology.

[3]  T. Arakawa,et al.  Effect of additives on protein aggregation. , 2009, Current pharmaceutical biotechnology.

[4]  L. Margulis,et al.  Aggregation of Recombinant Bovine Granulocyte Colony Stimulating Factor in Solution , 2002, Journal of protein chemistry.

[5]  E Schwarz,et al.  Advances in refolding of proteins produced in E. coli. , 1998, Current opinion in biotechnology.

[6]  Anurag Rathore,et al.  Use of the design‐of‐experiments approach for the development of a refolding technology for progenipoietin‐1, a recombinant human cytokine fusion protein from Escherichia coli inclusion bodies , 2009, Biotechnology and applied biochemistry.

[7]  M. Weiss,et al.  In Vitro Refolding of Human Proinsulin , 2003, The Journal of Biological Chemistry.

[8]  M. Rodrigues,et al.  Response surface analysis and simulation as a tool for bioprocess design and optimization , 2000 .

[9]  A. Vertès,et al.  Effect of operating variables on the yield of recombinant trypsinogen for a pulse-fed dilution-refolding reactor. , 2002, Biotechnology and bioengineering.

[10]  R. Gupta,et al.  Statistical medium optimization and production of a hyperthermostable lipase from Burkholderia cepacia in a bioreactor , 2002, Journal of applied microbiology.

[11]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[12]  Chaozhan Wang,et al.  High pH Solubilization and Chromatography-Based Renaturation and Purification of Recombinant Human Granulocyte Colony-Stimulating Factor from Inclusion Bodies , 2012, Applied Biochemistry and Biotechnology.

[13]  F. Marston.  The purification of eukaryotic polypeptides synthesized in Escherichia coli. , 1986, The Biochemical journal.

[14]  A. Divsalar,et al.  An efficient purification method for high recovery of Recombinant Human Granulocyte Colony Stimulating Factor from recombinant E. coli , 2010 .

[15]  Kouhei Tsumoto,et al.  Practical considerations in refolding proteins from inclusion bodies. , 2003, Protein expression and purification.

[16]  Neda Akbari,et al.  Efficient refolding of recombinant lipase from Escherichia coli inclusion bodies by response surface methodology. , 2010, Protein expression and purification.

[17]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[18]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[19]  Andree Ellert,et al.  Process optimization made easy: design of experiments with multi-bioreactor system BIOSTAT[reg] Qplus , 2011 .

[20]  Jing Chen,et al.  Cooperative effects of urea and L-arginine on protein refolding. , 2009, Protein expression and purification.

[21]  S. Singh,et al.  Solubilization at high pH results in improved recovery of proteins from inclusion bodies of E. coli , 2008 .

[22]  I. Pastan,et al.  A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. , 1992, Analytical biochemistry.

[23]  M. Narasu,et al.  A purification method for improving the process yield and quality of recombinant human granulocyte colony‐stimulating factor expressed in Escherichia coli and its characterization , 2008, Biotechnology and applied biochemistry.

[24]  A. Banerjee,et al.  Evaluation of refolding conditions for a human recombinant fusion cytokine protein, promegapoietin‐1a , 2008, Biotechnology and applied biochemistry.

[25]  L. Saso,et al.  Helicobacter pylori EstV: Identification, Cloning, and Characterization of the First Lipase Isolated from an Epsilon-Proteobacterium , 2007, Applied and Environmental Microbiology.

[26]  Marcel Ottens,et al.  Size-exclusion simulated moving bed chromatographic protein refolding , 2010 .

[27]  Xiangyang Wang,et al.  Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation , 2008, Biotechnology progress.

[28]  Aurélie Hermant,et al.  A high-throughput protein refolding screen in 96-well format combined with design of experiments to optimize the refolding conditions. , 2011, Protein expression and purification.

[29]  Michael Hoffmann,et al.  Rapid translation system: a novel cell-free way from gene to protein. , 2004, Biotechnology annual review.

[30]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[31]  A. Bahrami,et al.  Process development for production of human granulocyte-colony stimulating factor by high cell density cultivation of recombinant Escherichia coli , 2008, Journal of Industrial Microbiology & Biotechnology.

[32]  K. Yamaguchi,et al.  Purification and characterization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derivatives: KW-2228 and other derivatives. , 1998, Bioscience, biotechnology, and biochemistry.

[33]  J. Kane,et al.  Formation of recombinant protein inclusion bodies in Escherichia coli , 1988 .

[34]  Anurag S Rathore,et al.  Roadmap for implementation of quality by design (QbD) for biotechnology products. , 2009, Trends in biotechnology.

[35]  E D Clark,et al.  Protein refolding for industrial processes. , 2001, Current opinion in biotechnology.